|
January 17, 2025
CMS Announces 15 Additional Drugs Selected for Medicare Drug Price Negotiations in Continued Effort to Lower Prescription Drug Costs for Seniors
Today, the Centers for Medicare & Medicaid Services (CMS), announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations. In accordance with the Inflation Reduction Act, the negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027. Between November 2023 and October 2024, about 5.3 million people with Medicare Part D coverage used these drugs to treat a variety of conditions, such as cancer and type 2 diabetes. These selected drugs accounted for about $41 billion in total gross covered prescription drug costs under Medicare Part D, or about 14%, during that time period. When combined with the total gross covered prescription drug costs under Medicare Part D of the 10 drugs selected for the first cycle of negotiations over that same time period, this represents over a third of total gross covered prescription drug costs under Medicare Part D.
The selected drug list for the second cycle of negotiations is:
- Ozempic; Rybelsus; Wegovy
- Trelegy Ellipta
- Xtandi
- Pomalyst
- Ibrance
- Ofev
- Linzess
- Calquence
- Austedo; Austedo XR
- Breo Ellipta
- Tradjenta
- Xifaxan
- Vraylar
- Janumet; Janumet XR
- Otezla
View a CMS fact sheet on the drugs selected for the Medicare Drug Price Negotiation Program at: https://www.cms.gov/files/document/factsheet-medicare-negotiation-selected-drug-list-ipay-2027.pdf
More information on the Medicare Drug Price Negotiation Program is available at https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation.
Negotiation Data Elements and Drug Price Negotiation Process ICR Approved
The Negotiation Data Elements and Drug Price Negotiation Process approved ICR is available for viewing on OMB’s website. Click “all” to see full details. For initial price applicability year 2027, data submissions from participating drug companies of the selected drugs must be provided to CMS by March 1, 2025. Members of the public may also submit evidence about the selected drugs and their alternative treatments by March 1, 2025, via a web link that will be available through CMS.gov after the selected drug list is published. For initial price applicability year 2027, CMS will issue an initial written offer no later than June 1, 2025 and statutory written counteroffers, if applicable, will be due from participating manufacturers of the selected drugs 30 days after receipt of the initial offer.
|
